La vendita allo scoperto per CSL dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CSL. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CSL (OTC:CSLLY) Azioni, Report sulle vendite allo scoperto

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

CSL Ltd

Chubb Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) shares are trading lower by 5% to $275.89 going into the close of Monday&#8217;s session. Shares of insurance companies are trading lower while Floridians experience evacuation orders as Category 5 <a href="https://www.benzinga.com/markets/equities/24/10/41209505/hurricane-milton-is-floridas-second-storm-in-two-weeks-how-disney-theme-parks-insurance-companie">Hurricane Milton</a> approaches the state. The region is still recovering from damage due to Hurricane Helene.
What Happened: Shares of Chubb, one of the world's largest property and casualty insurers, fell today as Hurricane Milton intensified and headed toward Florida&#8217;s Gulf Coast. This comes less than two weeks after Hurricane Helene made landfall in the state, raising concerns over back-to-back financial pressures on insurers.
Chubb, known for its extensive portfolio of property, flood, and catastrophe insurance, faces heightened risk from these powerful storms. Florida is one of the company&#8217;s key markets for homeowner and commercial property insurance, and the potential damage from Hurricane Milton—expected to be a Category 4 or 5 storm—could lead to a surge in claims. 
The cumulative effect of Helene and Milton, both major hurricanes, could significantly impact Chubb's profitability in the fourth quarter.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/10/41214476/will-kamala-harriss-media-blitz-including-60-minutes-and-call-her-daddy-improve-her-2024-el">Will Kamala Harris&#8217;s Media Blitz, Including &#8217;60 Minutes&#8217; And &#8216;Call Her Daddy,&#8217; Improve Her 2024 Election Prospects?</a>
Hurricane Helene caused significant but manageable damage, leading to initial relief among insurers. However, the threat posed by Milton is amplifying concerns. Meteorologists expect Milton to affect a larger geographic area, particularly the Tampa Bay region, and the storm's size and intensity suggest higher levels of destruction, including wind damage, flooding and business interruptions. 
Given that Chubb provides comprehensive hurricane coverage, it could face hundreds of millions of dollars in claims.
What Else: Chubb has long been regarded as one of the most financially resilient insurers, with robust reinsurance arrangements and capital reserves to manage catastrophic events. However, consecutive hurricanes of this magnitude could pressure its underwriting performance and trigger larger-than-anticipated payouts, hurting its combined ratio—a key measure of profitability in the insurance industry. 
If Milton causes extensive infrastructure damage, Chubb could see a higher volume of claims than initially forecasted.
Additionally, the cost of handling claims, such as deploying adjusters and addressing policyholder needs in hard-hit areas, can inflate Chubb&#8217;s expenses. Given the already strained resources from Hurricane Helene, the added burden from Milton raises fears of longer recovery timelines and potentially larger economic losses.
Investors are cautious as Chubb&#8217;s exposure to natural disasters remains a key risk to the company's financial outlook. While home improvement and utility stocks may see gains due to increased demand for repairs and backup energy systems, Chubb and other insurers are vulnerable to unexpected, substantial losses from back-to-back hurricanes.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41213960/stocks-slip-as-oil-prices-surge-10-year-yields-cross-4-energy-sector-outperforms-whats-driving-m">Stocks Slip As Oil Prices Climb, 10-Year Yields Cross 4%; Energy Sector Outperforms: What&#8217;s Driving Markets Monday?</a>
<h2 class="wp-block-heading">How To Buy CB Stock</h2>
By now you're likely curious about how to participate in the market for Chubb &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CB has a 52-week high of $294.18 and a 52-week low of $205.64.

News

Why Chubb (CB) Stock Is Down 5% Today

Barclays analyst Theresa Chen maintains Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) with a Equal-Weight and raises the price target from $29 to $32.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Kodiak Gas Services, Raises Price Target to $32

Barclays analyst Theresa Chen maintains HF Sinclair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) with a Equal-Weight and lowers the price target from $53 to $44.

DINO

Barclays Maintains Equal-Weight on HF Sinclair, Lowers Price Target to $44

Macro Economic Events

Politics

Global

Economics

General

Senior U.S. Intelligence Official Says U.S. Assesses That China Is Not Seeking To Influence Outcome Of U.S. Presidential Election

Goldman Sachs analyst Eric Sheridan maintained a Buy rating on Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) and a price target of $430 (up from $425).
Ahead of its third-quarter 2024 earnings report, Sheridan previewed current industry data, addressed key investor debates, and highlighted the potential revenue contribution from a deluxe tier for Spotify over the long term.
Since its last earnings report, Spotify stock has outperformed (+13% versus the SPX +2% over the same period), which continues a pattern of the past 12 months with Spotify stock +142% versus the SPX +35%, the analyst noted.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/41095043/spotify-recovers-after-3-hour-outage-impacting-thousands-of-users" rel="noreferrer noopener">Spotify Recovers After 3-Hour Outage Impacting Thousands of Users</a>
He said Spotify's stock performance is anchored around a few key narratives that continue to build momentum.
Spotify is the clear global audio platform leader, which Sheridan expects to translate into elements of scaled compounded user growth, rising engagement across multiple format structures, and pricing power for his operating forecast period.
Coming out of its late 2023 operating costs restructuring, Spotify is beginning to show much of the gross and operating margin trajectory that the company has discussed as medium or long-term goals dating back over the last 3-5 years, with forward opportunities around efficiencies, segment revenue scale, and yield or return from prior period investment cycles as drivers of outsized multi-year margin improvements in years to come
The analyst also flagged the potential for a more consistent shareholder return policy that closely mirrors its global TMT peer group in the coming years.
Going into this earnings report, Sheridan noted investors focused on management commentary on pricing and product decisions, gross margin results, and broader elements of the audio landscape in terms of broader platform scaling or evolution in the years ahead.
Sheridan projected fiscal 2024 revenue of 15.72 billion euros and EPS of 5.87 euros.
Price action:&nbsp;SPOT stock is down 1.94% at $364.24 at the last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41147159/netflix-disney-amazon-hit-by-philippines-new-12-tax-on-digital-providers" target="_blank" rel="noreferrer noopener">Netflix, Disney+, Amazon Hit By Philippine&#8217;s New 12% Tax On Digital Providers</a></li>
</ul>
Photo by esthermm on Shutterstock

Analyst Color

Eurozone

Reiteration

Tech

Trading Ideas

SPOT

Goldman Sachs Raises Forecast On Spotify, Cites User Engagement Growth and Potential Deluxe Tier Revenue

Barclays analyst Michael Leithead maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Equal-Weight and lowers the price target from $101 to $99.

Barclays Maintains Equal-Weight on LyondellBasell Industries, Lowers Price Target to $99

Barclays analyst Michael Leithead maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Equal-Weight and lowers the price target from $58 to $57.

Barclays Maintains Equal-Weight on Dow, Lowers Price Target to $57

Barclays analyst Lauren Lieberman maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Overweight and lowers the price target from $309 to $300.

Barclays Maintains Overweight on Constellation Brands, Lowers Price Target to $300

Barclays analyst Benjamin Budish maintains Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Equal-Weight and raises the price target from $169 to $175.

COIN

Barclays Maintains Equal-Weight on Coinbase Glb, Raises Price Target to $175

Shares of Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>) have risen 20.7% in the past three months compared with the industry&#39;s growth of 6.3%. The stock has also outperformed the sector and the S&amp;P 500 Index.
Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.
<h2>EXEL Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9a/80573.jpg?v=2113034342" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Cabometyx Boosts EXEL</h2>
Cabometyx maintained its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma (RCC) in 2023. This was mainly attributable to its use in combination with Bristol Myers&#39;&nbsp;Opdivo in the first-line setting. The drug also maintained growth in the hepatocellular carcinoma indication.
BMY&#39;s Opdivo is one of the leading immuno-oncology drugs, approved for various oncology indications.
Management is also focused on the label expansion of Cabometyx. The FDA accepted EXEL&#39;s supplemental new drug application (sNDA) for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced extra-pancreatic NET (epNET). The FDA assigned a standard review with a target action date of April 3, 2025. The FDA also granted the orphan drug designation to cabozantinib for the treatment of pNET.
A potential label expansion should further propel its growth prospects.
Exelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq (atezolizumab), for metastatic castration-resistant prostate cancer.
<h2>EXEL Makes Encouraging Pipeline Progress</h2>
The pipeline progress has been impressive as well, as Exelixis looks to expand its oncology portfolio beyond Cabometyx.
Other promising candidates in Exelixis&#39; pipeline zanzalintinib, a next-generation oral TKI and XL309. In the first half of 2025, Exelixis intends to initiate a phase III study, STELLAR-311, to evaluate zanzalintinib compared with everolimus as a first oral therapy in patients with pNET and epNET.
The company also plans to advance phase I efforts for XL309 and XB010.
EXEL decided to discontinue the development of XB002. It plans to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and its growing pipeline.
The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Exelixis&#39; Efforts to Boost Shareholder Value</h2>
Exelixis is also making efforts to increase shareholder value through repurchases.&nbsp; At the end of the second quarter, Exelixis completed its 2024 share repurchase program, having repurchased 20.3 million shares of the company&#39;s common stock for a total of $450 million.
Consequently, the company returned $1 billion to shareholders since the initial $550 million stock repurchase program was authorized in March 2023.
The board of directors has authorized the repurchase of up to an additional $500 million of the company&#39;s common stock through the end of 2025.
<h2>Valuation &amp; Estimates</h2>
Going by the price/sales ratio, EXEL&#39;s shares currently trade at 3.64x forward sales, higher than its mean of 3.34x and the biotech industry&#39;s 1.79x.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/80575.jpg?v=206418566" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share has increased to $1.83 from $1.79 over the past 30 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/37/80578.jpg?v=1325426803" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Conclusion</h2>
Large biotech companies are generally considered safe havens for investors interested in this sector. EXEL is a good stock to buy now, with good fundamentals and growth prospects.
The stock has performed well this year. Potential label expansion of Cabometyx should boost its growth. The company&#39;s efforts to expand its portfolio are encouraging as well. The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Zacks Rank &amp; Other Key Picks</h2>
EXEL currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the biotech sector are Alnylam Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) and Krystal Biotech (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), both carrying a Zacks Rank #1 (Strong Buy) at present.
ALNY&#39;s loss per share estimate for 2024 has narrowed from $1.20 to 63 cents in the past 60 days and the same for 2025 has narrowed from 34 cents to 27 cents.
Krystal Biotech&#39;s earnings per share for 2024 have increased to $2.38 from $1.98 in the past 90 days. Shares of KRYS have surged 42.8% year to date.
<a href="https://www.zacks.com/stock/news/2346907/exelixis-gains-20-7-in-three-months-is-this-the-right-time-to-buy?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346907">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Large Cap

Mid Cap

Management

Markets

ALNY

EXEL

KRYS

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

- Reuters Citing Judge And Attorney&nbsp;

Legal

$BTC

$ETH

$FTT

Crypto Exchange FTX's Liquidation Plan Receives Court Approval; Will Fully Repay Customers With Up To $16B In Recovered Assets

WIIM

CAKE

CBRL

WING

Shares of restaurant stocks are trading lower possibly amid overall market weakness due to a rise in the 10-year Treasury yield.

Barclays analyst Benjamin Budish maintains Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) with a Overweight and raises the price target from $125 to $147.

Barclays Maintains Overweight on Tradeweb Markets, Raises Price Target to $147

Contracts

STLA

UAW Says Members At Stellantis' Denver PDC Voted By 97% To Authorize International UAW To Call A Strike If The Union Cannot Reach A Settlement With Co

Select Medical Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) short percent of float has risen 4.3% since its last report. The company recently reported that it has 2.62 million shares sold short, which is 3.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Select Medical Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728328522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Select Medical Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Select Medical Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Select Medical Hldgs's peer group average for short interest as a percentage of float is 4.22%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Select Medical Hldgs's Recent Short Interest

GoDaddy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) short percent of float has fallen 6.81% since its last report. The company recently reported that it has 3.30 million shares sold short, which is 3.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.26 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>GoDaddy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728328517_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GoDaddy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GoDaddy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, GoDaddy's peer group average for short interest as a percentage of float is 6.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

GDDY

How Is The Market Feeling About GoDaddy?

Comfort Systems USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) short percent of float has fallen 25.66% since its last report. The company recently reported that it has 485 thousand shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Comfort Systems USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728328513_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Comfort Systems USA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Comfort Systems USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Comfort Systems USA's peer group average for short interest as a percentage of float is 5.52%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Comfort Systems USA's Recent Short Interest

Lennar (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/len#NYSE">LEN</a>) has headwinds in 2024, including margin pressure, but that is the worst news. While the housing market at large is tepid, conditions favor home builders, driving business, cash flow, and capital returns. Looking forward, there is a catalyst for 2025 in FOMC rate cuts.
High rates and affordability impact consumer demand today, but the headwind is expected to become a tailwind as the rate-cut process progresses. To paraphrase comments from Lennar CEO Stuart Miller, the market is only expected to strengthen over time as affordability improves.&nbsp;
<h2>Lennar Outperforms in Q3; Guidance Underwhelms</h2>
Lennar had a solid quarter in Q3, with deliveries and backlog growing compared to the prior year. The company reported 49.4 billion in net revenue for a gain of 7.7% over last year, outpacing expectations by 260 basis points. The gain was driven by a 16% increase in deliveries offset by a &quot;slightly&quot; lower average selling price impacted by mix and incentives. Mix and incentives also impacted the margin, which contracted compared to last year but less than the consensus forecast reported by MarketBeat.
The new home gross margin contracted by 190 basis points, offset by improved SG&amp;A. The net margin on home sales contracted by 180 basis points, leaving net earnings up 5% and ahead of the consensus. The GAAP EPS of $4.26 is up 10%, including mark-to-market impact and other one-offs, but the adjusted is still strong at $3.90, flat YoY, and $0.33, or nearly 1000 basis points above the average forecast. The takeaway is that cash flow remains robust despite normalization following two years of intense activity, and the guidance remains favorable despite falling short of the consensus forecast.&nbsp;
The company guidance is underwhelming relative to the consensus estimates but expects a sequential improvement in delivery and flat margins compared to Q3. While tepid relative to expectations, the guidance implies cash flow sufficient to sustain fortress-quality operations and value-enhancing capital returns. Capital return in Q3 included $519 million in share repurchases, not including the dividend, and helped to reduce the average count by 4.5% YoY.&nbsp;
<h2>Lennar&#39;s Building Value for Shareholders</h2>
Lennar&#39;s positive cash-flow quarter allowed it to build shareholder value while paying dividends, repurchasing shares, and improving balance sheet health. The balance sheet highlights include a net cash position, no debt on the revolving facility, and improved equity despite the more than doubling treasury shares. Equity is up 3.15% and is expected to continue growing over time.&nbsp;
Assuming that the FOMC tailwind begins to impact the market soon, capital returns could easily accelerate in 2025. The dividend payment is less than 5% of earnings, and the total capital return for the quarter is less than 50%, leaving ample room for increases without earnings growth. The consensus for 2025 is for greater than 15% growth and is likely a cautious estimate given the outlook for interest rates.&nbsp;
<h2>Analysts Sentiment Drives Lennar Higher</h2>
The consensus price sentiment and price target for Lennar are a little misleading. The rating is pegged at Hold, down from a Moderate Buy, and the price target lags the price action. However, the rating slipped due to an influx of new reports initiated at Hold, with price targets leading the consensus higher. The consensus is up 35% compared to last year and 7.5% since the Q3 release, leading the market to the high-end range and a new all-time high. With 75% of the fresh revisions ranging from $190 to $235, the new high will likely be reached; the question is when.
The technical action is suggestive, with the market trending higher and winding up for its next move. The caution is that recent action looks like a rising wedge and may signal a correction is near. Up 200% in the last two years and trading at record levels, the market is ripe for a correction. In that scenario, targets for support and rebounding are $180, $170, and $165. A move below $165 could lead to $140 and a deep-value opportunity.&nbsp;
<img alt="Lennar LEN stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241001102946_chart-len-1012025.png" style="height:423px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/originals/why-lennar-stock-could-be-the-best-play-in-the-housing-market/">Why Lennar Stock Could Be the Best Play in the Housing Market</a>&quot; first appeared on MarketBeat.

Guidance

Dividends

Technicals

Why Lennar Stock Could Be the Best Play in the Housing Market

BURL

FORD

PLCE

ROST

SCVL

SHOO

ULTA

Shares of apparel-related stocks are trading lower possibly amid overall market weakness. Also, the sector could be pulling back from Friday's rally after the dockworkers reached a tentative deal to suspend their strike.

INDA

US State Dept Approves Potential Sale Of Torpedoes To India For $175M; Approves Potential Sale Of Electronic Attack Mission System To Italy For $680M; Approves Potential Sale Of Radar System To Romania For $110M

UBS analyst Laura Sutcliffe maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$330.00. The company's shares...

CSL (CMXHF) Receives a Buy from UBS

Morgans analyst Derek Jellinek maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$330.75. The company's sha...

Morgans Sticks to Their Buy Rating for CSL (CMXHF)

In a report released yesterday, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$329.62....

Jarden Reaffirms Their Buy Rating on CSL (CMXHF)

CSL Limited: Good Results Overshadowed By Below-Expectations Guidance

Project $1M: On Track After 2024's First Half

CSL  goes ex dividend tomorrow

In a report released yesterday, Shane Storey from Wilsons maintained a Hold rating on CSL (CMXHF – Research Report), with a price target of A$291.7...

Wilsons Sticks to Its Hold Rating for CSL (CMXHF)

Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The company's shar...

CSL (CMXHF) Receives a Buy from Citi

GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract

GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract (update)

ADBE

ADYEY

ADYYF

AMZN

ARKG

ASML

ASMLF

BABA

BABAF

CMXHF

CSLLY

DDOG

ENPH

FICO

GOOG

GOOGL

MELI

NNCSF

PMCUF

PMDIY

SHOP

SNOW

SNYNF

TCEHY

TCTZF

TEAM

VEEV

Small Cap

Press Releases

CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

CSL Joins Accumulus Synergy to Drive Industry Change

Mark Cuban Foundation and CSL Bring Free AI Bootcamp to Philadelphia Teens

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza

ARCT

Comments

CSL

Vendite allo scoperto

CSL (OTC:CSLLY) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO